Yosemite

We're excited to announce a $120 million oversubscribed financing to accelerate the development of our clinical pipeline of best-in-class ADCs for solid tumor malignancies, and proprietary CloakLink™ linker platform. The round was led by Yosemite, with participation from Abingworth, Ally Bridge Group, B Capital, Balyasny Asset Management L.P. , Merck., and SymBiosis, and existing investors Alexandria Venture Investments, AyurMaya Capital Management, DC Global Ventures, General Atlantic, and Surveyor Capital (a Citadel company). This latest funding follows a $75 million financing completed in December 2024, bringing Solve’s total capital raised to $321 million. Solve Therapeutics was founded to develop next-generation ADCs capable of addressing unique challenges presented by solid tumors. Traditional ADCs often face limitations related to payload hydrophobicity, including sub-optimal pharmacokinetics and plasma stability, which can compromise safety and efficacy. “We’re thrilled to partner with an outstanding syndicate of investors who share our vision for developing best-in-class ADCs,” said Dave Johnson, CEO & Co-Founder, Solve Therapeutics, Inc.. “Since founding the company, we’ve built a differentiated platform that combines next-generation ADC engineering, a superior hydrophilic linker system, and novel patient-selection diagnostics. This investment syndicate represents a strong endorsement of our science, our team, and our mission to develop more effective and safer targeted therapies for patients with solid tumors.” Read the press release: https://lnkd.in/er4cHehn #ADCs #oncology #biotech #lifesciences

What if we could make cancer non-lethal in our lifetime? That’s the mission driving Yosemite, an oncology-focused venture fund investing in the next generation of biotech and healthcare innovations. From at-home cervical cancer screening to breakthroughs in gene editing, Yosemite partners with companies moving science forward with precision and purpose. Meet the innovators leading this work in EC's Positive Sum No. 3. https://lnkd.in/eR4wm77n

Investor Matt Bettonville joins us to explore a bold new frontier in cancer care—where software can outperform pharmaceuticals. Alongside Reed Jobs at Yosemite, Matt is backing digital health tools that have shown survival outcomes rivaling, and in some cases surpassing, traditional cancer drugs. Yosemite’s hybrid model of venture investing and grantmaking is designed to fast-track innovation and ensure it reaches the people who need it most. We dive into:  📊 How digital interventions are reshaping survival curves  💸 The economics of drug development vs. digital therapeutics  🧬 Synthetic control arms and the future of clinical trials  🔍 Early detection tech—from liquid biopsies to at-home diagnostics  🌐 Why global leadership in healthcare innovation is up for grabs Listen here:  Apple: https://lnkd.in/gRkQM9aJ Spotify: https://lnkd.in/gy-C_fBD #DigitalTherapeutics #CancerInnovation #YosemiteFund #NextGenCures #EndCancer #HealthTech #TheHeartOfHealthcare

💙 At Daymark Health, we’ve always believed that exceptional cancer care is about more than what happens in the clinic. Patients and families spend hundreds of hours outside hospital walls — navigating uncertainty, stress, and everyday life while undergoing treatment. Too often, the system leaves them to carry that burden alone. That’s the gap Daymark was created to fill. We help meet our patients’ clinical, social, and mental health needs both virtually and in the home, in collaboration with oncologists and primary care providers. And today, we’re proud to share two milestones that bring us closer to that vision: ✨ We’ve raised our Series A funding round – led by Healthier Capital with The Blue Venture Fund with participation from Maverick Ventures, Yosemite, and Oncology Ventures. This capital will give us the resources to expand our team and build the kind of support system every patient deserves. 🤝 We’ve teamed up with our first health plan, offering in-network care to over 400k members with 2,500 in active treatment and ensuring they can all access comprehensive, personalized cancer care where they need it most. (More here: https://lnkd.in/giEk8wtA) These aren’t just business milestones – they’re steps toward a future where no one faces cancer alone. Where patients have care teams who walk with them not only through treatment, but through the day-to-day challenges and moments in between. To our investors, partners, and especially to the patients and families who inspire us every day: thank you for believing that better is possible. This is just the beginning. Read more about our news here 👉 https://lnkd.in/gByFrriR

Excited to share our first interim data in our Phase 1 for Huntington's patients, showing 62% lowering of mutant huntingtin protein ~ check out the release here! https://lnkd.in/erVfdjcS